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Introduction
Proteases have been increasingly recognized as important factors in pathophysiology of tumors diseases. Besides their contribution to cancer progression by the degradation of extracellular matrix proteins, there are now substantial evidences that certain proteases serve as signal molecules controling cell functions through specific membrane receptors, the protease-activated receptors. PARs are seven transmembrane spanning domain G proteincoupled receptors comprising four receptors named PAR-1, PAR2, PAR3 and PAR4 (1, 2) .
Thrombin is the physiological activator of PAR-1, PAR3 and PAR4 whereas PAR2 is activated by multiple trypsin-like-enzymes including trypsin and mast cell tryptase but not by thrombin. The mechanism of activation of PARs was initially established for PAR1 (3) and seems to be a paradigm for other PARs (1, 2, 4) . They are irreversibly activated by a proteolytic mechanism in which the protease binds to and cleaves the amino-terminal exodomain of the receptor. This cleavage generates a new N-terminal sequence that binds intramolecularly to the core receptor and serves as a tethered ligand. Synthetic activating peptides that mimic the tethered ligand domains of PAR1, PAR2, and PAR4 have been developed. The activation of PARs by these synthetic peptides APs is independent of receptor proteolysis (1, 2, 4) .
The importance of trypsin, a major serine protease, has been evidenced more recently in many cancers including in digestive tract tumors. Extra-pancreatic production of trypsin was shown in ovarian (5), lung (6) , gastric (7), colonic tumors (8) and also colon cancer cell lines (9, 10) . In addition, overexpression of exogenous trypsinogen cDNA in human gastric cancer cells increases their tumorigenicity in nude mice (7) . Recently, it has been shown that down regulation of trypsin (11) or serine protease inhibitors suppress carcinogenesis in many different in vivo and in vitro assay systems (12, 13) .
We have demonstrated that trypsin acting at PAR2 is a very robust growth factor for human colon cancer cells (14) . These data supported the idea that some serine proteases should now be considered as crucial contributors to the development of human colon cancer. However, the cellular pathways that transmit to the nucleus of colon cancer cells the proliferative signal induced by activation of PAR2 have not been elucidated yet. In this context, the purpose of the present study was to explore the signaling pathways downstream of PAR2 which lead to colon cancer cell proliferation. By using the human colon cancer cell line HT-29 as a model (14, 15), we showed that activation of PAR2 by its physiological activator trypsin or by the synthetic activating peptide AP2 results in a series of events that includes MMP-dependent release of TGF-α, transactivation of the EGF receptor and subsequent activation of ERK1/2. These data represent a breakthrough in the understanding of the role of PAR2 in controlling cell proliferation in colon cancer. They also highlight the role of the EGF receptor as a pivotal downstream integrator in the control of colon cancer cell proliferation by proteinase-activated receptors. 
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MAP-Kinase Western blots
For extracellular-regulated protein kinase (ERK1/2) phosphorylation, cells were grown in 6 cluster wells (Costar) at 50% confluency and serum-deprived for 48 hours prior to their activation with 10 nM trypsin or 100 µM AP2 for 5 min. 
EGF-R immunoprecipitation assay and Western blot
HT-29 cells were grown in 100 mm dishes at 50% confluency and serum-starved for 48 hours. Cells were then treated with PAR2 agonists (10 nM trypsin or 100 µM AP2) for 5 min at 37°C before being washed with cold PBS and lysed for 45 min on ice in the RIPA buffer containing Tris-HCl (50 mM), pH7.4, NaCl (150 mM), 1% (v/v) NP40, 0.25% (v/v) sodium deoxy-cholate, EGTA (1 mM), Na 3 VO4 (1 mM), NaF (1 mM) and proteases inhibitors. Cell lysates were cleared by spinning at 13,000 rpm for 10 min. EGF-Rs were precipitated overnight at 4°C from lysates with a polyclonal anti-EGF-R antibody coupled to protein G sepharose beads. The precipitates were separated on 7.5% SDS PAGE gel and transferred to nitrocellulose. Phosphorylated EGF-Rs were detected by Western blot with the anti-phospho-tyrosine monoclonal antibody 4G10. The total quantities of EGF-R were detected by Western blot with a polyclonal antibody against EGF-R. In some experiments, prior to the stimulation with the ligands, cells were pre-treated with AG1478 (3 µM), PP2 (10 µM) for 1 hour and were then stimulated with PAR2 agonists or EGF for 5 min.
TGF-α ELISA
HT-29 cells were seeded at 5,000 cells /well in 96 cluster wells (Costar) and allowed to attach for 3 days. They were starved in serum-free medium for 48 hours. To prevent the binding of released TGF-α to EGF-R, we pretreated cells with the anti-EGF-R binding domain antibody (10 µg/ml) for 2 hours prior to cell stimulation with PAR2 agonists. It was hypothesized (16) that this pretreatment increases the measurement of TGF-α in cell culture supernants. Cells were counted and the conditioned medium of different conditions was collected for measurement of TGF-α. ELISA for TGF-α was performed using commercially available Kit, according to the manufacture's instructions.
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Statistical analysis
All results are expressed as means ± S.E.M for a series of experiments. Differences between data were tested by Student's t-tests for unpaired data. A P value of < 0.05 was considered statistically significant.
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Results
Trypsin stimulates cell proliferation in HT-29 cells via ERK phosphorylation pathway
In previous studies we showed that trypsin acts as a growth factor for colon cancer cells through the activation of PAR2 (14). Since ERKs play a pivotal role in the pathway leading to growth factor-regulated proliferation, we investigated the implication of ERKs upon activation of PAR2. As shown in Figure 1A 
Activation of ERKs and cell proliferation induced by PAR2 agonists are attenuated by EGF-R tyrosine kinase inhibitors
We next determined whether PAR2-mediated ERKs activation is dependent on EGF-R kinase activity. As shown in figure 2 , the EGF-R kinase inhibitor tyrphostin AG1478 (3µM) abrogated the effects of PAR2 agonists on ERKs phosphorylation in HT-29 cells. EGF was used as a positive control to show the specificity of the inhibitor (Figure 2 ). To ascertain the implication of ERGF-R kinase in mitogenic pathway induced by PAR2, we inhibited EGF-R kinase activity with specific inhibitors and measured cell proliferation. As shown in Figure Darmoul Page 10 involvement of EGF-R tyrosine kinase activity in ERK activation and subsequent proliferative reponses induced by activation of PAR2.
Activation of PAR2 promotes the EGF-R phosphorylation
Since PAR2-mediated activation of ERK and cell proliferation could be influenced by inhibitors of the EGF-R tyrosine kinase, we sought to identify whether the activation of PAR2 results in EGF-R tyrosine phosphorylation. HT-29 cells were treated with trypsin, AP2 or EGF for 5 min and the cells were then lysed and assayed for tyrosine-specific phosphorylation of the EGF-R. The EGF-R in HT-29 cells became highly phosphorylated in response to EGF stimulation whereas PAR2 agonist-treatment resulted in moderate EGF-R tyrosine phosphorylation ( Figure 4A ). Further, we showed that inhibition of the EGF-R tyrosine kinase activity by AG1478 abolished the PAR2-dependent phosphorylation of the EGF-R in HT-29 cells ( Figure 4B ). As a control we checked that AG1478 also completely inhibited EGF-dependent phosphorylation of the EGF-R. It is concluded that activation of PAR2 leads to tyrosine phosphorylation of the EGF-R.
Blockade of the EGF-R ligand binding domain inhibits PAR2-mediated effects on cell proliferation and ERK1/2 phosphorylation
To determine the mechanism by which EGF-R is activated following the challenge of HT-29 cells with PAR2 agonists, we designed experiments to block the binding of EGF-R ligands to the extracellular domain of the EGF-R. We used a monoclonal antibody directed against the extracellular portion of the EGF-R. To avoid the bias of the proteolytic activity of the enzyme on the EGF-R antibodies, we performed these experiments only with PAR2 activating peptide AP2 and not with trypsin. As shown in Figure 5A , pre-incubation of HT-29 cells with the EGF-R blocking antibody reduced significantly AP2-induced HT-29 cell proliferation. In consonance with these data, pre-treating the cells with this antibody also inhibited AP2-stimulated ERK1/2 phosphorylation ( Figure 5B ). To test the efficiency of the antibody, we showed that the anti-EGF-R also inhibited EGF-induced ERK1/2 phosphorylation and cell proliferation ( Figure 5 ). These results provide strong evidence that 
A neutralizing antibody for TGF-α blocked PAR2-induced cell proliferation
The above described data showed that inhibition of EGF-R phosphorylation and blockade of EGF-R ligand binding domain inhibit PAR2-induced ERK1/2 activation and subsequent cell proliferation. We next investigated whether EGF-R transactivation upon activation of PARs is mediated by TGF-α release, the most abundant member of the EGF-R family ligands found in normal colon and colon carcinomas (18) . We first analyzed the involvement of TGF-α by blocking its biological activity with neutralizing antibodies. As shown in Figure 6A , treatment of HT-29 cells with TGF-α neutralizing antibodies strongly inhibited the AP2-induced cell proliferation. The TGF-α antibodies also had a small effect on control cells, suggesting that small amounts of ΤGF-α are constitutively secreted in the absence of PAR2 agonists. We tried to measure TGF-α under conditions in which TGF-α binding to the EGF-R was prevented by pre-incubating cells with EGF-R binding site antibodies (19) . Results showed that AP2 significantly enhanced TGF-α release as compared to control cells ( Figure 6B ). These findings suggest that PAR2 transactivate the EGF-R by causing the extracellular release of TGF-α.
PAR2-mediated ERK1/2 phosphorylation and cell proliferation involve MMPs.
A mechanism whereby the TGF-α ligand is released is thought to be the shedding of membrane-bound precursor by metalloproteinases (20) . Therefore, we tested the effect of the general metalloproteinases inhibitor batimastat in our model. As shown Figure 7 , batimastat abrogated cell proliferation induced by either synthetic agonists of PAR2 (AP2) or by the serine protease trypsin. In contrast, batimastat had no effect on exogenous EGF-or TGF-α-induced cell proliferation ( Figure 7A ). Batimastat was also tested on ERK1/2 phosphorylation induced by PAR2 agonists ( Figure 7B ). The MMPs inhibitor dramatically decreased ERK1/2 phosphorylation caused by PAR2 activators (trypsin or AP2). As expected, batimastat had no effect on EGF-induced ERK1/2 phosphorylation ( Figure 7B ).
These studies suggest that EGF-R transactivation induced by PAR agonists involves MMPmediated EGF-R ligand cleavage and correlates with our previous experiments which showed a reduction in AP2-induced cell number in the presence the TGF-α blocking antibody.
Effect of Src inhibitor on PAR agonist-induced EGF-R phosphorylation, ERK1/2 activation and subsequent cell proliferation
In addition to EGF-R activation, non receptor tyrosine kinases such as Src can be 
Discussion
We recently showed that trypsin, acting at protease-activated receptor PAR2, is a potent growth factor for human colon cancer cells (14). In the present study, we expand upon these findings to elucidate the mechanism(s) whereby PAR2 control colon cancer cell proliferation. We found that PAR2 agonists transactivate the epidermal growth factor receptor (EGF-R) through a pathway that includes matrix metalloproteinase-dependent cleavage and release of TGF-α which in turn activates the EGF-R and downstream MAPKs cascade leading to cell proliferation.
The different steps of the pathway leading to cell proliferation after activation of PARs have been analyzed using pharmacological enzyme inhibitors and neutralizing antibodies. 
